Bioventus (BVS) AI Stock Analysis

• Market Cap: $576.65M
• Dividend Yield: N/A
• Average Volume (3M): 390.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 8.60%
• EPS Growth: -42.76%
• Country: US
• Employees: 930
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): 0.08
• Shares Outstanding: 66,357,610
• 10 Day Avg. Volume: 586,934
• 30 Day Avg. Volume: 390,695
• PEG Ratio: <0.01
• Price to Book (P/B): 0.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.39
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 0.24
• Enterprise Value/Gross Profit: 1.43
• Enterprise Value/Ebitda: 3.90
• 1Y Price Target: $11.00
• Price Target Upside: 56.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 50 Neutral
• Price Target: $7.00 ▼(-0.28%Downside)

Bioventus' overall stock score reflects significant financial challenges with high leverage and declining cash flow. While positive earnings call insights and strategic growth in key segments offer some optimism, the technical analysis and valuation remain weak, indicating potential risks ahead.

Positive Factors

Business Strategy

The company is shifting from a recovery story to an execution story, succeeding in improving commercial execution across major business units.

Financial Performance

Bioventus is expected to deliver significant cash flow acceleration by lowering inventory, interest expense, and one-time cash costs.

Product Development

Bioventus has financial breathing room to invest in commercial and R&D efforts, helping it remain competitive.

Negative Factors

Distributor Orders

Pain Treatments growth benefited from above-normal distributor orders, which is expected to negatively impact Q1 expectations with lower distributor orders anticipated.

Earnings Expectations

Adjusted EBITDA is expected to be weaker due to revenue headwinds and tough comparisons with reduced spending levels from the previous year.

Revenue Challenges

Q1/H1 organic revenues should be more challenged given two fewer selling days, pull-forward of HA orders, and continued BGS distributor choppiness.

Bioventus Business Overview & Revenue Model

Company Description

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Bioventus generates revenue through the sale of its medical devices and biologic products to healthcare providers, including hospitals, clinics, and orthopedic specialists. The company's key revenue streams include product sales in the areas of bone healing, joint pain treatment, and bone graft solutions. Bioventus collaborates with healthcare professionals to ensure the effective integration of their products into treatment regimes, thereby driving sales. Additionally, Bioventus may engage in strategic partnerships and licensing agreements to expand its product offerings and market reach, which can also contribute to its earnings.

Bioventus Financial Statement Overview

Summary

Bioventus is facing financial challenges with negative EBIT and declining revenue growth. The high debt-to-equity ratio indicates financial risk, although the positive free cash flow provides some stability. Overall, financial difficulties and high leverage necessitate strategic adjustments.

Income Statement

Bioventus has faced challenges with profitability, as evidenced by negative EBIT and net income margins in TTM (Trailing-Twelve-Months). Despite a stable gross profit margin around 67%, the company struggles with operating efficiency. The revenue growth rate shows a declining trend, indicating potential sales stagnation.

Balance Sheet

The debt-to-equity ratio is significantly high at 2.33 in TTM, suggesting high leverage and potential financial risk. However, the equity ratio stands at 21.4%, indicating a moderate proportion of equity financing. The negative return on equity reflects ongoing profitability issues.

Cash Flow

The cash flow statement reveals a positive free cash flow, yet it's decreasing year-over-year, indicating diminishing cash generation capacity. The operating cash flow to net income ratio is positive, showing some efficiency in converting earnings into cash, despite overall negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	567.70M	573.28M	512.35M	512.12M	430.90M	321.16M
Gross Profit	381.13M	388.23M	328.19M	331.08M	302.71M	233.52M
EBITDA	38.13M	-49.55M	-23.07M	-121.61M	45.48M	52.06M
Net Income	-31.61M	-33.54M	-156.23M	-158.70M	19.38M	16.41M
Balance Sheet
Total Assets	691.41M	727.96M	810.91M	1.37B	1.23B	494.47M
Cash, Cash Equivalents and Short-Term Investments	22.80M	41.58M	36.96M	30.19M	43.93M	86.84M
Total Debt	345.93M	335.63M	394.85M	418.07M	357.68M	188.38M
Total Liabilities	505.94M	542.35M	589.79M	960.43M	692.07M	350.31M
Stockholders Equity	148.14M	147.94M	173.59M	325.24M	458.92M	144.16M
Cash Flow
Free Cash Flow	23.93M	37.79M	7.98M	-25.06M	15.62M	51.13M
Operating Cash Flow	25.47M	38.80M	15.34M	-13.54M	22.99M	71.80M
Investing Cash Flow	23.14M	22.96M	15.81M	-116.44M	-283.76M	-20.50M
Financing Cash Flow	-49.39M	-54.58M	-26.65M	62.08M	273.37M	-29.57M

Bioventus Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Neutral. The current price of 7.02 is above the 20-day moving average (MA) of 6.68, above the 50-day MA of 6.78, and below the 200-day MA of 9.72, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.65 is Neutral, neither overbought nor oversold. The STOCH value of 73.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BVS.

Bioventus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIBN	65 Neutral	$787.09M	―	-15.96%	―	22.60%	41.26%
KIDS	64 Neutral	$556.81M	―	-11.33%	―	31.28%	-81.86%
AXGN	59 Neutral	$497.80M	―	-7.22%	―	18.81%	67.41%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
BVS	50 Neutral	$576.65M	―	-19.79%	―	8.60%	-42.76%
OFIX	49 Neutral	$435.69M	―	-27.82%	―	5.85%	-8.92%
AVNS	48 Neutral	$571.11M	45.80	-36.78%	―	1.34%	-530.36%

Bioventus Corporate Events

Bioventus Holds Annual Meeting, Elects Directors

On June 3, 2025, Bioventus, Inc. held its Annual Meeting of Stockholders, where approximately 89.76% of the outstanding shares were represented. During the meeting, stockholders elected Class I directors to the Board and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (BVS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.